rs10742814 - CELF1
Magnitude 2.2 · 1 study on file
Reported associations
-
Cross-trait genomic modeling reveals the polygenic architecture and systemic impact of MASLD - Unknown journal (n.d.) · Unknown authors · PubMed 41686896
ABSTRACT: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a globally prevalent disease, yet its genetic architecture remains incompletely characterized. We integrated genome-wide association study data from multiple cohorts totaling nearly 3 million individuals of European ancestry and applied cross-trait genomic modeling of hepatic fat and seven cardiometabolic traits to construct an MASLD-specific polygenic architecture. We identified 128 risk variants across 100 loci and prioritized 55 effector genes, including established (e.g., PNPLA3 and TM6SF2) and previously unreported candidates (e.g., NRXN3 and FRMD5). A phenome-wide scan of the MASLD polygenic risk score revealed broad associations spanning hepatic, cardiometabolic, renal, endocrine, and neuropsychiatric sy
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Lifestyle
-
metabolic health optimization Moderate
MTAG is driven by metabolic dysfunction; weight loss and physical activity reduce disease risk and progression
maintain healthy BMI; aim for 150 minutes moderate aerobic activity weekly
Screening
-
liver function and steatosis Moderate
rs10742814-G allele increases metabolic dysfunction-associated steatotic liver disease risk
liver ultrasound and function tests annually